{
  "domain": "pharmacology",
  "version": "0.2.0",
  "description": "Quantitative priors for receptor binding, dose-response, drug metabolism, and pharmacokinetics",
  "priors": [
    {
      "param": "CBD_VDAC1_Kd",
      "value": 11.0,
      "unit": "uM",
      "type": 1,
      "source": "Rimmerman et al. 2013, BMC Neuroscience"
    },
    {
      "param": "CBD_TRPV1_Kd",
      "value": 2.0,
      "unit": "uM",
      "type": 1,
      "source": "Bisogno et al. 2001, British Journal of Pharmacology"
    },
    {
      "param": "CBD_TRPV2_EC50",
      "value": 3.7,
      "unit": "uM",
      "type": 1,
      "source": "Qin et al. 2008, PNAS"
    },
    {
      "param": "CBD_PPARgamma_EC50",
      "value": 5.0,
      "unit": "uM",
      "type": 2,
      "source": "O'Sullivan 2016, British Journal of Pharmacology (estimated)"
    },
    {
      "param": "CBD_therapeutic_window",
      "value": [1.0, 10.0],
      "unit": "uM",
      "type": 1,
      "source": "Clinical pharmacokinetic range, multiple studies"
    },
    {
      "param": "CBD_5HT1A_EC50",
      "value": 16.0,
      "unit": "uM",
      "type": 1,
      "source": "Russo et al. 2005, serotonin receptor agonism"
    },
    {
      "param": "CBD_oral_bioavailability",
      "value": [0.06, 0.19],
      "unit": "fraction",
      "type": 1,
      "source": "Millar et al. 2018, Frontiers in Pharmacology"
    },
    {
      "param": "CBD_half_life",
      "value": [18, 32],
      "unit": "hours",
      "type": 1,
      "source": "Taylor et al. 2018, pharmacokinetic review"
    },
    {
      "param": "Hill_coefficient_standard",
      "value": 1.0,
      "unit": "dimensionless",
      "type": 0,
      "source": "Standard Hill equation; n=1 for non-cooperative single-site binding"
    },
    {
      "param": "CYP3A4_inhibition_threshold",
      "value": 1.0,
      "unit": "uM",
      "type": 1,
      "source": "Yamaori et al. 2011, CBD inhibits CYP3A4-mediated metabolism"
    },
    {
      "param": "doxorubicin_IC50_MCF7",
      "value": 0.5,
      "unit": "uM",
      "type": 1,
      "source": "Standard chemotherapy reference, MCF-7 breast cancer cells"
    },
    {
      "param": "cisplatin_IC50_A549",
      "value": 5.0,
      "unit": "uM",
      "type": 1,
      "source": "Standard reference, A549 lung adenocarcinoma"
    },
    {
      "param": "therapeutic_index_minimum",
      "value": 10.0,
      "unit": "ratio",
      "type": 0,
      "source": "FDA guidance: TD50/ED50 > 10 for adequate safety margin"
    }
  ]
}
